Matching articles for "Duopa"

Drugs for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • February 22, 2021;  (Issue 1618)
The motor symptoms of Parkinson's disease (PD) are caused primarily by degeneration of dopaminergic neurons in the substantia nigra. The nonmotor symptoms of the disease are thought to be caused by...
The motor symptoms of Parkinson's disease (PD) are caused primarily by degeneration of dopaminergic neurons in the substantia nigra. The nonmotor symptoms of the disease are thought to be caused by degeneration of other neurotransmitter systems. No disease-modifying drugs are available for treatment of PD.
Med Lett Drugs Ther. 2021 Feb 22;63(1618):25-32 | Show Full IntroductionHide Full Introduction

Comparison Table: Drugs for Parkinson's Disease (online only)

   
The Medical Letter on Drugs and Therapeutics • February 22, 2021;  (Issue 1618)
...
View the Comparison Table: Drugs for Parkinson's Disease
Med Lett Drugs Ther. 2021 Feb 22;63(1618):e1-9 | Show Full IntroductionHide Full Introduction

Istradefylline (Nourianz) for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • February 10, 2020;  (Issue 1591)
The FDA has approved istradefylline (Nourianz — Kyowa Kirin), an oral adenosine A2A receptor antagonist, for use as an adjunct to carbidopa/levodopa in adults with Parkinson's disease (PD) who experience...
The FDA has approved istradefylline (Nourianz — Kyowa Kirin), an oral adenosine A2A receptor antagonist, for use as an adjunct to carbidopa/levodopa in adults with Parkinson's disease (PD) who experience "off" episodes. Istradefylline is the first adenosine A2A receptor antagonist to be approved in the US; it has been available in Japan since 2013.
Med Lett Drugs Ther. 2020 Feb 10;62(1591):20-3 | Show Full IntroductionHide Full Introduction

Inhaled Levodopa (Inbrija) for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • May 20, 2019;  (Issue 1572)
The FDA has approved Inbrija (Acorda), an orally inhaled dry-powder formulation of levodopa, for intermittent treatment of "off" episodes in patients with Parkinson's disease (PD) being treated...
The FDA has approved Inbrija (Acorda), an orally inhaled dry-powder formulation of levodopa, for intermittent treatment of "off" episodes in patients with Parkinson's disease (PD) being treated with carbidopa/levodopa (Sinemet, and others).
Med Lett Drugs Ther. 2019 May 20;61(1572):73-4 | Show Full IntroductionHide Full Introduction

Drugs for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • November 20, 2017;  (Issue 1534)
The motor symptoms of Parkinson's disease (PD) are caused primarily by degeneration of dopaminergic neurons in the substantia nigra. The nonmotor symptoms of the disease are thought to be caused...
The motor symptoms of Parkinson's disease (PD) are caused primarily by degeneration of dopaminergic neurons in the substantia nigra. The nonmotor symptoms of the disease are thought to be caused by degeneration of other neurotransmitter systems.
Med Lett Drugs Ther. 2017 Nov 20;59(1534):187-94 | Show Full IntroductionHide Full Introduction

Comparison Table: Drugs for Parkinson's Disease (online only)

   
The Medical Letter on Drugs and Therapeutics • November 20, 2017;  (Issue 1534)
...
View the Comparison Table: Drugs for Parkinson's Disease
Med Lett Drugs Ther. 2017 Nov 20;59(1534):e194-6 | Show Full IntroductionHide Full Introduction

In Brief: Duopa - A Carbidopa/Levodopa Enteral Suspension for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • August 3, 2015;  (Issue 1474)
The FDA has approved Duopa (Abbvie), a carbidopa/levodopa enteral suspension, for treatment of motor fluctuations in patients with advanced Parkinson's disease (PD). It has been available in Europe since...
The FDA has approved Duopa (Abbvie), a carbidopa/levodopa enteral suspension, for treatment of motor fluctuations in patients with advanced Parkinson's disease (PD). It has been available in Europe since 2001.

In patients with advanced PD, emptying of the stomach may be delayed and unpredictable, which can affect the rate and amount of absorption of carbidopa/levodopa and its efficacy. To bypass the stomach, the new formulation is delivered through a nasojejunal (NJ) tube or percutaneous endoscopic gastrostomy with jejunal (PEG-J) tube.

A randomized, double-blind, active-controlled, 12-week trial in 66 levodopa-responsive patients with advanced PD and motor complications found that Duopa reduced daily mean "off" time from baseline significantly more than oral immediate-release carbidopa/levodopa (by 4.04 hours vs 2.14 hours). Mean "on" time without troublesome dyskinesia increased by 4.11 hours with the new formulation and by 2.24 hours with immediate-release tablets.1

Duopa is available in a 100-mL single-use cassette containing 4.63 mg of carbidopa and 20 mg of levodopa per mL. It should be administered over 16 hours through a NJ or PEG-J tube with the CADD-Legacy 1400 portable infusion pump. Patients should be switched to oral immediate-release carbidopa/levodopa before starting Duopa; the labeling has instructions for conversion from immediate-release tablets to Duopa. The maximum recommended daily dose of levodopa is 2000 mg (1 cassette/day). Patients must also take oral immediate-release carbidopa/levodopa in the evening after disconnecting the pump. The medication cassette should be stored in the refrigerator and removed 20 minutes before administration.

One month's supply of Duopa costs $6054;2 PEG-J tube insertion and administration-related expenses will significantly increase the cost of treatment.3

  1. CW Olanow et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 2014; 13:141.
  2. Approximate WAC. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. July 5, 2015. Reprinted with permission by First Databank, Inc. All rights reserved. ©2015. www.fdbhealth.com/policies/drug-pricing-policy.
  3. F Valldeoriola et al. Cost analysis of the treatments for patients with advanced Parkinson's disease: SCOPE study. J Med Econ 2013; 16:191.


Download complete U.S. English article

Med Lett Drugs Ther. 2015 Aug 3;57(1474):112 | Show Full IntroductionHide Full Introduction